表紙
市場調查報告書

膀胱癌:開發中產品分析

Bladder Cancer - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232863
出版日期 內容資訊 英文 1626 Pages
訂單完成後即時交付
價格
Back to Top
膀胱癌:開發中產品分析 Bladder Cancer - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 1626 Pages
簡介

本報告提供膀胱癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

膀胱癌概要

治療藥的開發

膀胱癌:企業開發中的治療藥

膀胱癌:大學/機關研究中的治療藥

膀胱癌:開發中產品概況

膀胱癌:企業開發中的產品

膀胱癌:大學/機關研究中的產品

膀胱癌的治療藥的開發企業

膀胱癌:治療藥的評估

藥物簡介

膀胱癌:最近的開發平台趨勢

膀胱癌:暫停中的計劃

膀胱癌:開發中止的產品

膀胱癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11703IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2019, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 73, 85, 1, 2, 81, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 4, 1, 13 and 3 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bladder Cancer - Overview
    • Bladder Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bladder Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bladder Cancer - Companies Involved in Therapeutics Development
    • Bladder Cancer - Drug Profiles
    • 4SC-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 9-ING41 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AB-154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bladder Cancer - Dormant Projects
  • Bladder Cancer - Discontinued Products
  • Bladder Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Dec 09, 2019: Sesen Bio initiates rolling submission of BLA for Vicinium to FDA
      • Dec 05, 2019: FerGene announces pivotal phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS Ta/T1) achieving a complete response at three months
      • Dec 04, 2019: Sesen Bio completes successful CMC Type B pre-BLA Meeting with FDA
      • Dec 02, 2019: FDA grants priority review to Merck's supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC)
      • Nov 27, 2019: Theralase researchers receive recognition for recent scientific publications
      • Nov 26, 2019: Cancer Research UK: Bladder cancer treatment rejected for routine use on NHS in England
      • Nov 08, 2019: Neon Therapeutics announces updated data presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
      • Nov 06, 2019: 4D pharma: Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA
      • Nov 05, 2019: Sesen Bio Announces successful type C meeting with FDA for Vicinium
      • Oct 23, 2019: EpiVax Oncology announces three abstracts accepted for presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
      • Oct 21, 2019: Bavarian Nordic reports Phase II bladder cancer trial data
      • Oct 07, 2019: London Health Sciences Centre launches as newest clinical study site for phase II Non-Muscle Invasive Bladder Cancer clinical study
      • Oct 01, 2019: Roche's Tecentriq performs well in untreated bladder cancer
      • Oct 01, 2019: Theralase files Investigational New Drug application with the FDA
      • Sep 30, 2019: Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bladder Cancer, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Bladder Cancer - Pipeline by 4D Pharma Plc, H2 2019
  • Bladder Cancer - Pipeline by 4SC AG, H2 2019
  • Bladder Cancer - Pipeline by Aadi Bioscience Inc, H2 2019
  • Bladder Cancer - Pipeline by AbbVie Inc, H2 2019
  • Bladder Cancer - Pipeline by Abivax SA, H2 2019
  • Bladder Cancer - Pipeline by Actuate Therapeutics Inc, H2 2019
  • Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2019
  • Bladder Cancer - Pipeline by Advaxis Inc, H2 2019
  • Bladder Cancer - Pipeline by Agenus Inc, H2 2019
  • Bladder Cancer - Pipeline by AIM ImmunoTech Inc, H2 2019
  • Bladder Cancer - Pipeline by Alligator Bioscience AB, H2 2019
  • Bladder Cancer - Pipeline by Alphamab Oncology, H2 2019
  • Bladder Cancer - Pipeline by Altor Bioscience LLC, H2 2019
  • Bladder Cancer - Pipeline by Amrita Therapeutics, H2 2019
  • Bladder Cancer - Pipeline by Andes Biotechnologies, H2 2019
  • Bladder Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
  • Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2019
  • Bladder Cancer - Dormant Projects, H2 2019
  • Bladder Cancer - Discontinued Products, H2 2019
  • Bladder Cancer - Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development for Bladder Cancer, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top